A Phase II, Double-blind, Randomized, Placebocontrolled, Parallel-group, Single-center Study to Evaluate the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in Multiple Sclerosis (MS) Patients With Spasticity-related Symptoms

Trial Profile

A Phase II, Double-blind, Randomized, Placebocontrolled, Parallel-group, Single-center Study to Evaluate the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in Multiple Sclerosis (MS) Patients With Spasticity-related Symptoms

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Phytotech
  • Most Recent Events

    • 13 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
    • 13 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
    • 13 Jun 2017 Planned initiation date changed from 1 Apr 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top